The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis

Background: Extensive-disease small-cell lung cancer (ED-SCLC) has been known to be rapid progression and relapse, despite highly sensitive to chemotherapy. Amrubicin (AMR), a third-generation synthetic anthracycline, was accepted as a feasible alternative compared with the standard first-line chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ji-Feng, Zhou, Jian-Jun, Li, Xin-Ai, Hu, Li-Hui, Wen, Meng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611712/
https://www.ncbi.nlm.nih.gov/pubmed/31303766
http://dx.doi.org/10.2147/OTT.S200601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611712/
https://www.ncbi.nlm.nih.gov/pubmed/31303766
http://dx.doi.org/10.2147/OTT.S200601

Ejemplares similares